Business
60 Degrees Pharmaceuticals Expands Access to ARAKODA® with GoodRx Partnership
GoodRx to offer prescription savings of up to 30% for ARAKODA® (tafenoquine)Collaboration designed to lower patient out-of-pocket costs and expand the reach
About this update from Goodrx Holdings, Inc.
[{"type":"text","content":"GoodRx to offer prescription savings of up to 30% for ARAKODA® (tafenoquine)Collaboration designed to lower patient out-of-pocket costs and expand the reach of Company’s marketing strategyPartnership will improve the affordability of ARAKODA at over 70,000 pharmacies nationwide for people planning travel to malaria-endemic regions WASHINGTON, Feb. 02, 2026 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60 Degrees Pharma” or the “Company”), a pharmaceutical company focused on developing new medicines for vector-borne disease, today announced a partnership with GoodRx (Nasdaq: GDRX), the leading platform for prescription savings in the U.S., to offer eligible consumers savings of up to 30% on ARAKODA® (tafenoquine). ARAKODA is the only FDA-approved, broad spectrum, once-weekly prescription malaria prevention on the U.S. market. ARAKODA is a treatment of choice by travelers departing to regions of the world where malaria is endemic. Caused by the bite of the Anopheles mosquito, malaria is one of the most serious, life-threatening infectious diseases in the world. It is a constant threat to those living in malaria-endemic regions and to international travelers to those areas. If left untreated, it can progress to severe malaria, which is often fatal. Starting February 2, 2026, eligible patients can use GoodRx to access a low self-pay price for ARAKODA at more than 70,000 pharmacies nationwide, or can have the medication delivered to their home, when available. About ARAKODA (tafenoquine) Tafenoquine is approved for malaria prophylaxis in the United States under the product name ARAKODA®. The safety of the approved regimen of tafenoquine for malaria prophylaxis has been assessed in five separate randomized, double-blind, active comparator or placebo-controlled trials for durations of up to six months. Tafenoquine was discovered by Walter Reed Army Institute of Research, and the current study was funded by the United States Army Medical & Materiel Development Activity. Tafenoquine was approved for malaria prophylaxis in 2018 in the United States as ARAKODA® and in Australia as KODATEF®. Both were commercially launched in 2019 and are currently distributed through pharmaceutical wholesaler networks in each respective country. They are available at retail pharmacies as a prescription-only malaria prevention...